Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of “Moderate Buy” from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received an average rating of “Moderate Buy” from the eighteen research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and sixteen have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $65.7647.

RARE has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Bank of America cut their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th. Wedbush reissued a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Finally, Robert W. Baird lowered their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, insider John Richard Pinion sold 10,029 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares in the company, valued at $2,508,592.80. This represents a 8.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Erik Harris sold 10,539 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $240,289.20. Following the transaction, the executive vice president directly owned 89,515 shares in the company, valued at approximately $2,040,942. The trade was a 10.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 104,958 shares of company stock worth $2,394,858 over the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 29,984 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Ultragenyx Pharmaceutical by 6.0% in the second quarter. Envestnet Asset Management Inc. now owns 29,956 shares of the biopharmaceutical company’s stock worth $1,089,000 after purchasing an additional 1,698 shares during the period. Fox Run Management L.L.C. bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at $607,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Ultragenyx Pharmaceutical by 7.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 441 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $309,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Ultragenyx Pharmaceutical Trading Down 1.7%

NASDAQ RARE opened at $21.34 on Tuesday. Ultragenyx Pharmaceutical has a 52 week low of $18.41 and a 52 week high of $42.37. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -3.65 and a beta of 0.16. The company has a 50-day moving average price of $23.01 and a two-hundred day moving average price of $28.82.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.39) EPS. As a group, equities research analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.